Open-label, Multicentre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline in Neonates and Young Infants with Late-Onset Sepsis

Trial Profile

Open-label, Multicentre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline in Neonates and Young Infants with Late-Onset Sepsis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Ceftaroline fosamil (Primary)
  • Indications Sepsis
  • Focus Adverse reactions
  • Sponsors AstraZeneca; Pfizer
  • Most Recent Events

    • 06 Oct 2016 This trial is completed in Spain, according to Eudra record.
    • 11 Aug 2016 Planned End Date changed from 1 Jul 2017 to 1 Oct 2017.
    • 11 Aug 2016 Planned primary completion date changed from 1 Jul 2017 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top